secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001819790-25-000120
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Q3 2025: XDEMVY sales $118.7M, +147% YoY; net loss narrows to $0.30/share
--------------------------------------------------------------------------------

- XDEMVY net sales of $118.7M (Q3 2024: $48.1M); >103,000 bottles delivered to patients.
- Net loss of $12.6M vs $23.4M; diluted EPS $(0.30) vs $(0.61) in prior-year quarter.
- Cash, equivalents & marketable securities of $401.8M as of Sept 30, 2025.
- Phase 2 trial of TP-04 for ocular rosacea starting Dec 2025; Phase 2 of TP-05 for Lyme disease in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979025000120/0001819790-25-000120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979025000120/tars-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001819790-25-000120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer